Predictors of Progression in Barrett's Esophagus with Low‐Grade Dysplasia: Results from a Multicenter Prospective BE Registry. (June 2017)

• Record Type: Journal Article
• Authors: Krishnamoorthi, Rajesh; Lewis, Jason T; Krishna, Murli; Crews, Nicholas J; Johnson, Michele L; Dierkhising, Ross A; Ginos, Brenda F; Wang, Kenneth K; Wolfsen, Herbert C; Fleischer, David E; Ramirez, Francisco C; Buttar, Navtej S; Katzka, David A; Iyer, Prasad G
• Is Part Of: American journal of gastroenterology. Volume 112:Number 6(2017)
• Publication Date: 2017-06
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.1038/ajg.2017.84
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : Objectives: Low‐grade dysplasia (LGD) is a risk factor for progression in Barrett's esophagus (BE). Progression estimates however vary and predictors of progression are not well established. We aimed to assess predictors of progression in a multicenter BE‐LGD cohort. Methods: All subjects with LGD (diagnosed by a GI pathologist) in a prospective BE registry were identified. Progression was defined development of HGD/EAC more than 12 months after index date of LGD diagnosis. Clinical, endoscopic factors and impact of histologic review by an independent panel of two GI pathologists were assessed as predictors of progression. Cox proportional hazard models were used to assess their association with risk of progression. Results: 244 BE‐LGD subjects met inclusion criteria. Their mean age was 63.2 years. 205 (84%) were males. The median follow up was 4.8 years. Fifty six patients were diagnosed with HGD/EAC in less than 12 months, while 14 progressed to HGD/EAC after 12 months, with an overall annual risk of progression of 1.2%. 29% of LGD subjects were downgraded to non‐dysplastic and the remaining re‐confirmed as LGD or indefinite dysplasia. The risk of progression in the reconfirmed LGD group was eight fold higher (hazards ratio: 7.6, 95% CI: 1.5–139.4) in a propensity score stratified model. Conclusions: In this large BE‐LGD cohort, progression risk increased substantially when an additional panel of two expert GI pathologists re‐confirmed a LGD diagnosis. These BE subjects may be candidates for endoscopic therapy. LGD was a marker of prevalent HGD/EAC in 18% of patients.